Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership

elong ACN Newswire
HONG KONG, Dec 11, 2024 - (ACN Newswire via SeaPRwire.com) – As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by robust R&D capabilities and exceptional commercialization expertise.Breakthroughs in Renal Disease…
Read More

Combating customer harassment: Fujitsu, Toyo University and Kokoro Balance Research Institute launch field trial on AI-powered training program

admin JCN Newswire
Tokyo and Kawasaki, Japan, Dec 11, 2024 - (JCN Newswire via SeaPRwire.com) -  Fujitsu Limited, Toyo University Incorporated Educational Institution (Toyo University) and Kokoro Balance Research Institute today announced the commencement of a field trial on December 3, 2024, to develop a Training Program for Coping with Customer Aggression. This…
Read More

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

elong ACN Newswire
KNOXVILLE, Tenn., Dec 10, 2024 - (ACN Newswire via SeaPRwire.com) - VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye…
Read More

Provision of the First Template Function Adapted to the IFRS Sustainability Disclosure Standards in Japan (IFRS S1 and S2) on the Sustainable Finance Platform

admin JCN Newswire
TOKYO, Dec 10, 2024 - (JCN Newswire via SeaPRwire.com) - The Association for Promotion of Sustainable Finance Platform (AP-SFPF) and Hitachi, Ltd. (Hitachi) today announced that we will begin providing the first template feature adapted to the IFRS sustainability disclosure standards in Japan (IFRS S1 and S2*1) formulated by the…
Read More

Jacobio Pharma Presents Early-Stage Myelofibrosis Data for BET Inhibitor at ASH 2024 “`

elong Business
BEIJING, SHANGHAI and BOSTON, December 8, 2024 — Jacobio Pharma (1167.HK), a clinical-stage oncology company specializing in developing therapies targeting previously undruggable targets, today announced preliminary Phase I data for its BET inhibitor, JAB-8263, in the treatment of myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting…
Read More